Innovation in

Nanomedicine & Drug Delivery

  • LinkedIn Social Icon
  • Twitter

We are a nanotech lab in the University of Pennsylvania's Departments of Medicine and Pharmacology.  

     Our goal is to provide solutions to the Achille's heel of drug therapy and the reason most fail in clinical trials:  Drugs that are intended to work on one organ or cell type actually distribute all over the body, where they cause off-target side effects that limit the maximal dose and impede therapy.  To solve this pervasive problem, we aim to innovate new nanotechnologies and drug delivery tools to massively concentrate drugs at their intended site of action, thus minimizing side effects and maximizing therapy.  We design our nanoscale drug carriers using tools from formulation chemistry, bioconjugate chemistry, protein engineering, and computational modeling.  We test our technologies in rodent and large animal models, as well as ex vivo human organs, always with the goal of iteratively improving our nanotechnology designs so they can reach patients. 

     We focus particularly on a very large class of diseases that suffers the most from the drug distribution problem:  acute critical illnesses (ACIs), which are diseases that can immediately lead to death or permanent organ dysfunction.  ACIs include ARDS (the lung inflammation that kills in COVID-19), stroke, heart attack, sepsis, post-surgical conditions, trauma, and many more.

     Since our goal is to get technologies to patients, we believe in the importance of partnering with industry.  We have multiple industry partners we work with closely, providing our trainees with industry experience and contacts.  We also love entrepreneurship, as the lab's PI, Jake Brenner, has founded 3 funded companies (including one FDA approval), and teaches medical technology entrepreneurship at Penn.

Please join us in the fight, building nanotechnologies to defeat these terrible diseases!

 

Innovation in

Nanomedicine & Drug Delivery

  • LinkedIn Social Icon
  • Twitter

We are a nanotech lab in the University of Pennsylvania's Departments of Medicine and Pharmacology.  

     Our goal is to provide solutions to the Achille's heel of drug therapy and the reason most fail in clinical trials:  Drugs that are intended to work on one organ or cell type actually distribute all over the body, where they cause off-target side effects that limit the maximal dose and impede therapy.  To solve this pervasive problem, we aim to innovate new nanotechnologies and drug delivery tools to massively concentrate drugs at their intended site of action, thus minimizing side effects and maximizing therapy.  We design our nanoscale drug carriers using tools from formulation chemistry, bioconjugate chemistry, protein engineering, and computational modeling.  We test our technologies in rodent and large animal models, as well as ex vivo human organs, always with the goal of iteratively improving our nanotechnology designs so they can reach patients. 

     We focus particularly on a very large class of diseases that suffers the most from the drug distribution problem:  acute critical illnesses (ACIs), which are diseases that can immediately lead to death or permanent organ dysfunction.  ACIs include ARDS (the lung inflammation that kills in COVID-19), stroke, heart attack, sepsis, post-surgical conditions, trauma, and many more.

     Since our goal is to get technologies to patients, we believe in the importance of partnering with industry.  We have multiple industry partners we work with closely, providing our trainees with industry experience and contacts.  We also love entrepreneurship, as the lab's PI, Jake Brenner, has founded 3 funded companies (including one FDA approval), and teaches medical technology entrepreneurship at Penn.

Please join us in the fight, building nanotechnologies to defeat these terrible diseases!

©2020 by Brenner Bioengineering Lab